Johnson & Johnson has projected its lung cancer drug Rybrevant could achieve $5 billion in peak revenue. At the recent ASCO annual meeting, J&J executive Joshua Bauml explained his company’s strategy for this drug in lung cancer and beyond.
The post J&J’s Growth Strategy in Lung Cancer Borrows From Its Experience in Multiple Myeloma appeared first on MedCity News.
